The neutral endopeptidase (EC 3.4.24.11) ('enkephalinase') is a membrane-bound metalloendopeptidase that is present in large amounts in the microvilli of the kidney proximal tubules. By immunizing mice with purified rabbit kidney brush-border membranes, we have obtained four different monoclonal antibodies that recognize this enzyme in dot-blot and Western-blot assays and can be used for immunoprecipitation of neutral endopeptidase from crude kidney solubilizates. One of these monoclonal antibodies (2B12) allows the labeling of proximal tubule cells with colloidal gold particles. This monoclonal antibody also binds to native brush-border membrane vesicles (which are mostly in the right-side-out configuration) and recognizes an epitope which is destroyed after reduction and alkylation of the protein. By contrast, all three other monoclonal antibodies (21G10, 23B11 and 22E2) compete for another epitope of neutral endopeptidase that is not exposed at the extracytoplasmic surface either in intact cells or in sealed brush-border vesicles. Permeabilization of the vesicles with digitonin, however, restores the full binding activity. Binding of these antibodies is not altered by prior reduction and alkylation of the protein. Taken together, these results strongly suggest that the 2B12 monoclonal antibody binds a conformational epitope located on the ectodomain of the enzyme, whereas the three others (21G10, 23B11 and 22E2) bind to a common or to overlapping epitopes located on the cytosolic domain. These results also demonstrate unambiguously the transmembrane nature of neutral endopeptidase.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0304-4165(88)90188-2 | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, No. 74, Linjiang Road, Chongqing, 400010, China.
Angiotensin receptor-neprilysin inhibitor (ARNI) and angiotensin II receptor blockers (ARB) are antihypertension medications that improve cardiac remodeling and protect the heart. However, at the early stage of hypertension, it is still unclear how these two drugs affect the transcriptomic profile of multiple organs in hypertensive rats and the transcriptomic differences between them. We performed RNA sequencing to define the RNA expressing profiles of the eight tissues (atrium, ventricle, aorta, kidney, brain, lung, white fat, and brown fat) in spontaneously hypertensive rats (SHRs) and SHRs treated with ARNI or ARB.
View Article and Find Full Text PDFFront Med (Lausanne)
January 2025
Department of Pharmacology, Faculty of Medicine, Kagawa University, Takamatsu, Japan.
Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a novel class of medications characterized by their dual action on major cardiorenal regulators, specifically the renin-angiotensin system (RAS) and the natriuretic peptide (NP) system. Sacubitril/valsartan, a pioneering ARNI, has demonstrated strong antihypertensive effect as well as superior efficacy in preserving renal function compared to RAS inhibitors in heart failure patients with reduced ejection fraction. Here, we gathered evidence on the impact of sacubitril/valsartan on the preservation of kidney function in patients with cardiorenal syndrome (CRS).
View Article and Find Full Text PDFESC Heart Fail
January 2025
Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
Aims: Heart failure (HF) patients may lack improvement of left ventricular (LV) ejection fraction (LVEF) despite optimal HF medication comprising an angiotensin receptor-neprilysin inhibitor (ARNI). Therefore, we aimed to identify key predictors for LV functional enhancement and prognostic reverse cardiac remodelling in HF patients on ARNI treatment.
Methods: We retrospectively analysed 294 consecutive patients with HF with reduced (HFrEF) or mildly reduced (HFmrEF) ejection fraction in our 'EnTruth' patient registry.
J Cardiothorac Surg
January 2025
Department of Cardiology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital, Heart Center of Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.
Objective: Impaired right ventricular (RV)-pulmonary arterial (PA) coupling, calculated by measuring the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP), can be used as an early indicator of right ventricular dysfunction (RVD) in patients with heart failure with a reduced ejection fraction (HFrEF). Patients suffering from HFrEF experience improvements in left ventricular (LV) function through the administration of sacubitril/valsartan therapy. In addition, the albumin-bilirubin (ALBI) score was associated with the fluid overload status and adverse clinical outcomes in patients with heart failure.
View Article and Find Full Text PDFESC Heart Fail
January 2025
Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group, Washington, DC, USA.
Aims: Guideline-directed medical therapy (GDMT) is recommended for all patients with heart failure with reduced ejection fraction (HFrEF). Despite this, little data exist describing GDMT use in diverse, real-world populations including the use of vasodilators, prescribed primarily to Black populations. We sought, among a diverse population of HFrEF patients, to determine (1) GDMT use rates and target dosing by medication class and (2) predictors of GDMT use and target dosing by medication class.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!